Relebactam 250 mg

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Intra-abdominal InfectionsPyelonephritisUrinary Tract Infections

Phase 2

Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)

CompletedNCT01505634

Merck Sharp & Dohme LLCPyelonephritis, Urinary Tract Infections

Start: 2012-05-16End: 2015-07-28Updated: 2019-05-24

Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)

CompletedNCT01506271

Merck Sharp & Dohme LLCIntra-abdominal Infections

Start: 2012-06-01End: 2014-08-12Updated: 2019-06-10

Related Papers

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

Journal of Antimicrobial Chemotherapy2017-04-26158 citations

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

Antimicrobial Agents and Chemotherapy2016-08-09177 citations